Since AURKA and MAL have been implicated in ovarian cancer pathology and are, therefore, functionally important rather than the outcome of a deregulation side effect, they are promising nominees to include in a panel of novel biomarkers for the detection of ovarian cancer. Here, AURKA is linked to ovarian carcinoma.